These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2642032)

  • 1. The FDA perspective on the development of stereoisomers.
    De Camp WH
    Chirality; 1989; 1(1):2-6. PubMed ID: 2642032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single enantiomer drugs: should they be developed?
    Khan AY; Preskorn SH; Wimalasena K
    Essent Psychopharmacol; 2006; 7(1):15-23. PubMed ID: 16989289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug regulation and policy formulation.
    Nightingale SL
    Milbank Mem Fund Q Health Soc; 1981; 59(3):412-44. PubMed ID: 7024847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs.
    Strong M
    Food Drug Law J; 1999; 54(3):463-87. PubMed ID: 11797710
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential properties of enantiomers of commercially available racemates.
    Gulati V
    J Indian Med Assoc; 2007 Apr; 105(4):173-4, 176. PubMed ID: 17822184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States.
    Rauws AG; Groen K
    Chirality; 1994; 6(2):72-5. PubMed ID: 8204416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA takes action against unapproved drugs.
    Meadows M
    FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How are drugs approved? Part 3. The stages of drug development.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chirality and its implications in transdermal drug development.
    Reddy IK; Kommuru TR; Zaghloul AA; Khan MA
    Crit Rev Ther Drug Carrier Syst; 2000; 17(4):285-325. PubMed ID: 10958245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incoming guidelines on chirality. A challenge for pharmacokinetics in drug development.
    Marzo A
    Arzneimittelforschung; 1994 Jun; 44(6):791-3. PubMed ID: 8053982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.
    Brocks DR
    Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of chirality in clinical pharmacology].
    Le Corre P; Sado P; Le Verge R
    J Pharm Belg; 1991; 46(5):331-47. PubMed ID: 1791526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and separation of optically active compounds. Part I.
    Gao Y; Boschetti E; Guerrier L
    Ann Pharm Fr; 1994; 52(4):184-203. PubMed ID: 7857027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug and antibiotic regulations--FDA. Proposed rule.
    Fed Regist; 1982 Oct; 47(202):46622-66. PubMed ID: 10262075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.